Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin to prevent contrast-associated acute kidney injury in acute coronary syndrome
IRCT20181026041471N2Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dapagliflozin in acute coronary syndrome (ACS) and Postcontrast Acute Kidney Injury (PC-AKI), sponsored by Tehran University of Medical Sciences. Started Aug 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
acute coronary syndrome (ACS)Postcontrast Acute Kidney Injury (PC-AKI)
Beyond the preview
Go deeper on IRCT20181026041471N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181026041471N2.